Structure Therapeutics (NASDAQ: GPCR)
Structure Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Structure Therapeutics Company Info
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
News & Analysis
Could Structure Therapeutics Become the Next Novo Nordisk?
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Structure Therapeutics Stock Could Rocket 88% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Structure Therapeutics has a long way to go before beating Wegovy.
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
It has genuine struggles ahead, but it has some actual value in hand as well.
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug.
Why Shares of Structure Therapeutics Are Soaring on Friday
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate.
Why Shares of Structure Therapeutics Rose Monday
The company's lead diabetes and weight-loss therapy may benefit from a decision by Pfizer.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.